Boehringer Ingelheim launches comprehensive support resources for people with idiopathic pulmonary fibrosis
October 20, 2014 |
RIDGEFIELD, CONN. - October 20, 2014 - Boehringer Ingelheim Pharmaceuticals, Inc. today announced that OFEV® (nintedanib) capsules are now commercially available in the United States. OFEV was approved by the U.S. Food and Drug Administration (FDA) on October 15, 2014 for the treatment of idiopathic pulmonary fibrosis (IPF). It is the only kinase inhibitor approved to treat IPF.
IPF is a rare and fatal lung disease that affects as many as 132,000 Americans. Most people with IPF only live three to five years after diagnosis. IPF typically affects men over the age of 65.
To support the launch of OFEV, Boehringer Ingelheim has established OPEN DOORS™, a comprehensive patient support program that provides a broad range of financial and nursing support services. One of the goals of this program is to help patients who are prescribed OFEV gain rapid and affordable access to the medicine.
Read the full press release here.